TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 282070
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg, orally)
Study: 282070
Drug: Nifedipine (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (sublingual route)
Study: 31207253
Drug: High soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High soy protein (HSP; 50 g)
Study: 31207253
Drug: Low soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low soy protein (LSP; 25 g)
Study: 31207253
Drug: Control (CON;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CON; 50 g carbohydrate)
Study: 25991760
Drug: Standard major
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard major haemorrhage therapy (STANDARD)
Study: 22664119
Drug: Deferiprone 75
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 75 mg/kg/day TDS orally with deferoxamine 30-50 mg/kg subcutaneously every other day
Study: 22664119
Drug: Deferoxamine 30-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine 30-50 mg/kg/day subcutaneously for 6-12 hours/day and 5-6 days per week
Study: 17524772
Drug: Straight scleral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Straight scleral injection
Study: 15374722
Drug: Endometrial laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial laser intrauterine thermal therapy (ELITT)
Study: 9539615
Drug: Acetyl starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl starch (ACS) 6% i.v. at 15 mL/kg up to 1000 mL
Study: 9539615
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (HES) 6% i.v. at 15 mL/kg up to 1000 mL
Study: 21411655
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg naloxone
Study: 7855219
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg naloxone
Study: 30671872
Drug: Two-hourly repositioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-hourly repositioning 24/7
Study: 28815282
Drug: 20 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg/day calcidiol
Study: 28815282
Drug: 40 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg/day calcidiol
Study: 28815282
Drug: 125 μg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 μg/week calcidiol
Study: 11254020
Drug: Inositol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (12 g)
Study: 8350363
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg daily for 2 or 5 years)
Study: 31282542
Drug: Dipyridamole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (100 mg 4 times a day)
Study: 31322200
Drug: Spirulina, curcumin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina, curcumin, and Boswellia supplement
Study: 28425818
Drug: 3-dose priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-dose priming and booster (3 + 1)
Study: 28425818
Drug: 2-dose priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-dose priming and booster (2 + 1)
Study: 28425818
Drug: 3-dose priming
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-dose priming without booster (3 + 0)
Study: 12617375
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham short-wave therapy for 30 minutes) combined with conventional physiotherapy
Study: 27048747
Drug: Control (current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (current combination antiretroviral therapy)
Study: 25149882
Drug: INSURE method
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INSURE method (Intubation, Surfactant administration and extubation)
Study: 22078337
Drug: Trigone-including injections
Normalized name: Trigonella foenum-graecum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigone-including injections of 500 U abobotulinumtoxinA diluted to 20ml
Study: 22078337
Drug: Trigone-sparing injections
Normalized name: Trigonella foenum-graecum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigone-sparing injections of 500 U abobotulinumtoxinA diluted to 20ml
Study: 22078337
Drug: Trigone-including injections
Normalized name: Trigonella foenum-graecum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigone-including injections
Study: 22078337
Drug: Trigone-including and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigone-including and trigone-sparing injections
Study: 7627386
Drug: Ranitidine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 100 mg IV twice a day for two days, followed by 150 mg orally twice a day for three days
Study: 28536723
Drug: Two-way SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-way SMS medication reminders
Study: 26384233
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol intake (0.4 g/kg)
Study: 20137473
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg recombination yeast hepatitis B vaccine (3 doses at 0 month, 1st month, 6th month)
Study: 18297891
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (usually in combination with folic acid)
Study: 18297891
Drug: Withholding iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding iron supplementation until treatment schedule is complete
Study: 11476462
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg q.d.
Study: 11476462
Drug: Oxatomide 25
Normalized name: oxatomide 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide 25 mg q.d.
Study: 9170765
Drug: TP (treatment-plan-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP (treatment-plan-related tasks)
Study: 9170765
Drug: UA (urine
Approvals — FDA: no, EMA: no, PMDA: no
Description: UA (urine samples testing negative for illicit drugs)
Study: 9170765
Drug: STD (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: STD (standard treatment)
Study: 23063633
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg daily of saw palmetto extract
Study: 23063633
Drug: 640 mg
Normalized name: glycerin 1640 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 640 mg daily of saw palmetto extract
Study: 23063633
Drug: 960 mg
Normalized name: glycerin 960 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960 mg daily of saw palmetto extract
Study: 18065796
Drug: Acetate-Free Biofiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate-Free Biofiltration with constant potassium (2.5 mEq/l) (AFB)
Study: 12972523
Drug: Gemcitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,250 mg/m2 IV on days 1 and 8, and cisplatin 100 mg/m2 IV on day 1 (GC arm)
Study: 12972523
Drug: Irinotecan 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 150 mg/m2 IV on day 1 and cisplatin 80 mg/m2 IV on day 1 (IC arm)
Study: 10358993
Drug: Specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific therapy and ultrasonic treatment (44 KHz, amplitude 2 microm to the paravertebral region and PT zones)
Study: 10358993
Drug: Specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific therapy only
Study: 8665055
Drug: rhDNase 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43)
Study: 8665055
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml excipient alone twice daily (n = 37)
Study: 8665055
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (rhDNase and control)
Study: 1874198
Drug: Frusemide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 0.5 mg kg‐1 at the onset of hypotension (Group F)
Study: 6352599
Drug: Azlocillin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azlocillin (18 g/day, intravenously)
Study: 6352599
Drug: Gentamicin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (3 to 5 mg/kg/day, intramuscularly)
Study: 30683195
Drug: Best Endovascular
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Endovascular Therapy
Study: 30683195
Drug: Best Surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Surgical Therapy
Study: 20160062
Drug: PCV chemotherapy
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV chemotherapy
Study: 18657891
Drug: Serum phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum phosphorus level greater than 6 mg/dL
Study: 18657891
Drug: Serum calcium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum calcium level greater than 11 mg/dL
Study: 18657891
Drug: Ca x
Normalized name: Base PCCA Xylifos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca x P product greater than 50 mg(2)/dL(2)
Study: 18657891
Drug: Intact parathyroid
Normalized name: Intact parathyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact parathyroid hormone levels
Study: 10510219
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (221 +/- 18 mg; range 60-360 mg)
Study: 10510219
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate 40 mg daily
Study: 10510219
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate 60 mg every 3 months
Study: 1763596
Drug: Ketamine 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.7 mg/kg BW i.v. before anaesthesia, and 0.35 mg/kg BW 15 and 30 min after the first dose
Study: 1763596
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 mg/kg BW i.v. before anaesthesia
Study: 31796519
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg IV every 21 days and Vorinostat 400 mg orally 5 days on and 2 days off during each 21-day cycle
Study: 28983665
Drug: Prebiotic vaginal
Normalized name: Suppository, Multi Ingredient Vaginal Suppository [VH ESSENTIALS PREBIOTIC VAGINAL SUPPOSITORIES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic vaginal gel (5 mg) plus three 250 mg metronidazole tablets per day for 7 days
Study: 28983665
Drug: Metronidazole tablet
Normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole tablet alone (three 250 mg tablets per day for 7 days)
Study: 18041436
Drug: Glucomannan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (1 g) before 75-g glucose load
Study: 18041436
Drug: Glucomannan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (3 g/day for 4 weeks)
Study: 9755295
Drug: Fleroxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (200 mg IV)
Study: 9755295
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg IV)
Study: 7823260
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin (ASA) administered daily for two weeks
Study: 3392236
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of loprazolam
Study: 3392236
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of loprazolam
Study: 30298608
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (ART at study enrollment)
Study: 30298608
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (ART when CD4 count fell below 350 cells/µL)
Study: 25760804
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg once daily)
Study: 25045726
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular injection of vitamin E + selenium 3 weeks prepartum
Study: 25045726
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of oral vitamin E from 3 weeks prepartum to parturition
Study: 25045726
Drug: Injective vitamin
Normalized name: vitamin A Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injective vitamin E + selenium with daily supplementation of oral vitamin E
Study: 9131946
Drug: S-flurbiprofen (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-flurbiprofen (75 mg)
Study: 9131946
Drug: R-flurbiprofen (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-flurbiprofen (75 mg)
Study: 25547003
Drug: Intraperitoneal raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal raltitrexed in normal saline (500 ml)
Study: 31931924
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (500 ml)
Study: 20818903
Drug: Double-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose clopidogrel (600 mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter)
Study: 20818903
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel (300 mg loading dose and 75 mg daily thereafter)
Study: 20818903
Drug: Higher-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose aspirin (300 to 325 mg daily)
Study: 20818903
Drug: Lower-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-dose aspirin (75 to 100 mg daily)
Study: 20818903
Drug: Higher-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose aspirin
Study: 20818903
Drug: Lower-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-dose aspirin
Study: 12663712
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (MACOP-B regimen)
Study: 12663712
Drug: Abbreviated chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (HDT-ASCT)
Study: 10362762
Drug: Men (M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men (M) and Women (W) matched by VO2 max (46.1 +/- 2.0 and 43.6 +/- 2.9 ml. kg‐1. min‐1)
Study: 10362762
Drug: Men (MF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men (MF) with higher fitness level (VO2 max of 59.1 +/- 1.8 ml. kg‐1. min‐1)
Study: 31567988
Drug: Sham electroacupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroacupuncture treatment
Study: 23560476
Drug: aqueous gel
Normalized name: Sulfacetamide Sodium/Sulfur 10%-5% Topical application Gel/Jelly [ROSULA AQUEOUS GEL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: aqueous gel
Study: 15351856
Drug: CYP2C9 genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C9 genotyping prior to initiation of warfarin therapy (genotyped group)
Study: 9145846
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg single dose)
Study: 9145846
Drug: Rufloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin (400 mg single dose)
Study: 3595697
Drug: Diclofenac (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (preoperative administration)
Study: 3595697
Drug: Diclofenac (postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (postoperative administration)
Study: 27566586
Drug: Endostar antiangiogenic
Normalized name: Menostar
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endostar antiangiogenic therapy combined with NP neoadjuvant chemotherapy
Study: 27566586
Drug: NP neoadjuvant
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP neoadjuvant chemotherapy alone
Study: 25070091
Drug: PA administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA administration
Study: 23583327
Drug: RECOS (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: RECOS (individualized therapy)
Study: 23583327
Drug: CRT (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT (general cognitive remediation therapy)
Study: 16873785
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (immediately premeal)
Study: 16873785
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (15 min postmeal)
Study: 14655784
Drug: Clobetasol cream
Normalized name: clobetasol Topical Cream
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol cream 0.05% and solution 0.05%
Study: 27128607
Drug: Mericitabine 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine 1,500 mg
Study: 27128607
Drug: Mericitabine 9,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mericitabine 9,000 mg
Study: 22187234
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (200 mg celecoxib and 20 mg doxycycline, both twice daily)
Study: 22187234
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice daily) only
Study: 21094838
Drug: High-dose antithymocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antithymocyte globulin (ATG) therapy plus shortened standard therapy (group 1)
Study: 21094838
Drug: High-dose ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATG therapy (group 1)
Study: 17426325
Drug: MK-0557 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0557 (1 mg/d)
Study: 7796643
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg twice daily for three months
Study: 7796643
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg twice daily and cyclopentylethinyl estriol (CEE3) 5 mg once a month for three months
Study: 2127789
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b treatment (3 million units, three times weekly, subcutaneously for 36 weeks)
Study: 2127789
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b treatment
Study: 28432265
Drug: Actovegin (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (2000 mg/d for ≤20 intravenous infusions followed by 1200 mg/d orally)
Study: 19593411
Drug: Adjunctive use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive use of denicotinized cigarettes
Study: 11028571
Drug: Levonorgestrel-releasing (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-releasing (20 μg/day) intrauterine system (LNG-20)
Study: 9198052
Drug: Intradermal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Study: 9198052
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Study: 9198052
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of intradermal schedule
Study: 1376843
Drug: Isradipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 1.25 mg
Study: 9848540
Drug: Metronidazole 250
Normalized name: metronidazole 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 250 mg plus Amoxicillin 500 mg, 3 times/day for a week
Study: 9848540
Drug: Metronidazole plus
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole plus Amoxicillin (M+A)
Study: 8024227
Drug: Calcium nadroparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium nadroparin (fixed dose: daily subcutaneous injection of 0.6 ml, i.e. 6150 anti‐Xa IU, n = 38)
Study: 8024227
Drug: Calcium nadroparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium nadroparin (weight-adjusted dose: 31.5 anti‐Xa IU/kg, n = 40)
Study: 8024227
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg as a single daily dose, n = 39)
Study: 1095134
Drug: Monofluorophosphate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monofluorophosphate (25 mg fluoride per day)
Study: 7562730
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fluoride treatment)
Study: 31153674
Drug: Typical hypocaloric
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical hypocaloric dietary treatment
Study: 31814707
Drug: AZD7594 (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7594 (1600 µg)
Study: 28407543
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis (6.9% THC, ∼54mg)
Study: 21689343
Drug: Patent blue
Normalized name: Patent Blue
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patent blue V dye injection
Study: 21689343
Drug: No patent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patent blue V dye injection
Study: 21689343
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after application of Carnoy's solution